Aclaris Therapeutics (ACRS): Bullish KOL Call - JMP

JMP Securities analyst, Donald Ellis, reiterated his Market Outperform rating on shares of Aclaris Therapeutis (NASDAQ: ACRS) after hosting a KOL call with Dr. Ted Rosen to discuss A-101’s opportunity in SK, common warts (CW), and Molluscum Contagiosum (MC).

The analyst stated that Dr. Rosen was highly positive and expects rapid adoption for SK followed closely by off-label use in CW and MC due in part to A-101’s safety profile and high clearance
and almost-clearance rates that appear to have acceptable efficacy.

No change to the price target of $39.

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $27.38 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Alico Inc. (ALCO) to Buy
• Gencor Industries (GENC) PT Raised to $19 at Freedom Broker
• FDA grants fast track status to Aclaris drug for lichen planus